{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:30:59Z","timestamp":1780486259191,"version":"3.54.1"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ctrv.2023.102619","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T04:46:02Z","timestamp":1692938762000},"page":"102619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"120","author":[{"given":"Pau","family":"Abrisqueta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Nadeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bosch-Schips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Cabirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrecia","family":"Y\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Quintanilla-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ctrv.2023.102619_b0005","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102619_b0010","unstructured":"Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 1928;4(4):285\u201392.7."},{"key":"10.1016\/j.ctrv.2023.102619_b0015","unstructured":"WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017."},{"key":"10.1016\/j.ctrv.2023.102619_b0020","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36(7):1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0025","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0030","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.ctrv.2023.102619_b0035","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0040","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102619_b0045","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102619_b0055","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjh.14062","article-title":"Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors","volume":"177","author":"Chan","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0065","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/PAS.0b013e31826cb1d1","article-title":"Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases","volume":"37","author":"Martinez","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0070","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0075","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3324\/haematol.2020.256388","article-title":"Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration","volume":"106","author":"Stephens","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0080","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b0085","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0095","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.ctrv.2023.102619_b0100","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0105","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102619_b0120","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0125","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102619_b0130","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0135","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.bbmt.2016.06.025","article-title":"Hematopoietic cell transplantation for Richter syndrome","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0140","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.clml.2017.10.002","article-title":"Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b0145","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2023.102619_b0150","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.2020010187","article-title":"Synergistic efficacy of the dual PI3K-\u03b4\/\u03b3 inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models","volume":"137","author":"Iannello","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0155","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.ctrv.2023.102619_b0160","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102619_b0165","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102619_b0170","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102619_b0175","doi-asserted-by":"crossref","unstructured":"Benjamini O, Shimoni A, Besser M ea. Safety and efficacy of CD19-CAR T cells in Richter's transformation after targeted therapy for chronic lymphocytic leukemia. In: American Society of hematology 62nd annual meeting and exposition. Abstract 545.2020.","DOI":"10.1182\/blood-2020-138904"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0180","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102619_b0185","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter's transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2023.102619_b0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102619_b0195","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0200","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0205","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0210","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2021.278304","article-title":"The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation","volume":"107","author":"Visentin","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2023.102619_b0215","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-018-3390-x","article-title":"Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales","author":"Federmann","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0220","doi-asserted-by":"crossref","DOI":"10.2217\/ijh-2018-0010","article-title":"Current trends in the management of Richter's syndrome","volume":"7","author":"Allan","year":"2018","journal-title":"Int J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b0225","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102619_b0230","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0235","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0240","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0245","first-page":"348","article-title":"Richter transformation of chronic lymphocytic leukemia in the era of novel agents","volume":"18","author":"Wang","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ctrv.2023.102619_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100824","article-title":"Revisiting Richter transformation in the era of novel CLL agents","volume":"49","author":"Petrackova","year":"2021","journal-title":"Blood Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2023.102619_b0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2222","article-title":"The pathology of transformation of indolent B cell lymphomas","volume":"33","author":"Gascoyne","year":"2015","journal-title":"Hematol Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2023.102619_b0260","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0265","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/his.13024","article-title":"Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102619_b0270","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3109\/10428194.2012.664845","article-title":"Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia","volume":"53","author":"Fan","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1309\/AJCPATRQWANW2O3N","article-title":"Cytogenetic and flow cytometry evaluation of Richter syndrome reveals MYC, CDKN2A, IGH alterations with loss of CD52, CD62L and increase of CD71 antigen expression as the most frequent recurrent abnormalities","volume":"143","author":"Woroniecka","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102619_b0280","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ajh.24473","article-title":"Histologic transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"91","author":"Agbay","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0285","first-page":"7540","article-title":"Richter transformation with c-MYC overexpression: report of three cases","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Path"},{"key":"10.1016\/j.ctrv.2023.102619_b0290","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","author":"Wang","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0295","first-page":"207","article-title":"De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct","volume":"147","author":"Matolcsy","year":"1995","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102619_b0300","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 Expression in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0305","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102619_b0310","first-page":"902","article-title":"Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity","volume":"6","author":"Cordone","year":"1992","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102619_b0315","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0320","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404435","article-title":"Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation","volume":"20","author":"Karlsson","year":"2006","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.ctrv.2023.102619_b0325","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2011-07-365437","article-title":"Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial","volume":"119","author":"Lepretre","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0330","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1097\/HS9.0000000000000473","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)","volume":"4","author":"Quinquenel","year":"2020","journal-title":"Hemasphere."},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0335","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2012.09127.x","article-title":"Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine","volume":"158","author":"Jamroziak","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0340","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","article-title":"Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature","volume":"156","author":"Bockorny","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102619_b0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","article-title":"Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion","volume":"55","author":"Xiao","year":"2016","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0350","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00000478-200405000-00018","article-title":"Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection","volume":"28","author":"de Leval","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0355","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-022-00616-6","article-title":"Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?","volume":"12","author":"King","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102619_b0360","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.humpath.2013.04.008","article-title":"Plasmablastic transformation of low-grade CD5+ B-cell lymphoproliferative disorder with MYC gene rearrangements","volume":"44","author":"Pan","year":"2013","journal-title":"Hum Pathol"},{"issue":"5\u20136","key":"10.1016\/j.ctrv.2023.102619_b0365","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0609.2001.00592.x","article-title":"Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome","volume":"67","author":"Robak","year":"2001","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0370","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000505683","article-title":"Chronic lymphocytic leukemia with divergent Richter's transformation into a clonally related classical Hodgkin's and plasmablastic lymphoma: a case report","volume":"13","author":"Gasljevic","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0375","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-4608(95)00202-2","article-title":"Clonal evolution of chronic lymphocytic leukemia to acute lymphoblastic leukemia","volume":"86","author":"Mohamed","year":"1996","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0380","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1309\/AJCPXE5VMONMVLZ0","article-title":"B-lymphoblastic leukemia in patients with chronic lymphocytic leukemia: a report of four cases","volume":"144","author":"Chakhachiro","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0385","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V78.3.797.797","article-title":"Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors","volume":"78","author":"Pistoia","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0390","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000205751","article-title":"Initial clonal acute lymphoblastic transformation of chronic lymphocytic leukemia with (11;14) and (8;12) chromosome translocations and acquired homozygosity","volume":"79","author":"Archimbaud","year":"1988","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ctrv.2023.102619_b0395","doi-asserted-by":"crossref","unstructured":"Skala SL, Ye JC, Stumph J, Macon WR, Quinones FR, Khachaturov V, et al. Combined tumors in hematolymphoid neoplasms: case series of histiocytic and Langerhans cell sarcomas arising from low-grade B-cell lymphoma. Clin Pathol 2019;12:2632010X19878410.","DOI":"10.1177\/2632010X19878410"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0400","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1309\/AJCPWQ0I0DGXBMHO","article-title":"Transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone","volume":"132","author":"Fraser","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0405","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.2011.102","article-title":"Clonally related histiocytic\/dendritic cell sarcoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a study of seven cases","volume":"24","author":"Shao","year":"2011","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0410","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.5858\/arpa.2018-0220-RA","article-title":"Histiocytic sarcoma: review, discussion of transformation from B-cell lymphoma, and differential diagnosis","volume":"142","author":"Skala","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0415","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","article-title":"Richter syndrome: pathogenesis and management","volume":"43","author":"Rossi","year":"2016","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2023.102619_b0420","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016 updated WHO classification of lymphoid neoplasias","volume":"35","author":"Quintanilla-Martinez","year":"2017","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0425","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/leu.2011.247","article-title":"Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays","volume":"26","author":"Ciccone","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102619_b0430","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","article-title":"Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib","volume":"4","author":"Hampel","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0435","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/bjh.16948","article-title":"Pseudo-Richter transformation of chronic lymphocytic leukaemia\/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall","volume":"191","author":"Barnea Slonim","year":"2020","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102619_b0440","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/sj.gt.3301241","article-title":"Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A","volume":"7","author":"Eling","year":"2000","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0445","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ajcp\/95.5.709","article-title":"Herpes simplex lymphadenitis","volume":"95","author":"Gaffey","year":"1991","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0450","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ajcp\/86.4.444","article-title":"Localized herpes simplex lymphadenitis","volume":"86","author":"Epstein","year":"1986","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0455","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/jh517","article-title":"Herpes simplex necrotic lymphadenitis masquerading as Richter's transformation in treatment-naive patients with chronic lymphocytic leukemia","volume":"8","author":"Hodgson","year":"2019","journal-title":"J Hematol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102619_b0460","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10428190903062083","article-title":"Concurrent herpes simplex viral lymphadenitis and chronic lymphocytic leukemia\/small lymphocytic lymphoma, mimicking large-cell (Richter) transformation","volume":"50","author":"Oo","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0465","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/his.13137","article-title":"Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature","volume":"70","author":"Salem","year":"2017","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0470","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajh.10006","article-title":"Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"68","author":"Joseph","year":"2001","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0475","article-title":"Herpes simplex virus causing necrotizing granulomatous lymphadenitis","volume":"14","author":"Parmar","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0480","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PAS.0000000000000140","article-title":"Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"38","author":"Boyer","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0485","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/PAS.0000000000001646","article-title":"Angioimmunoblastic T-Cell lymphoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a novel form of composite lymphoma potentially mimicking Richter syndrome","volume":"45","author":"Trimech","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0490","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1066896912464047","article-title":"Composite peripheral T-cell lymphoma not otherwise specified, and B-cell small lymphocytic lymphoma presenting with hemophagocytic lymphohistiocytosis","volume":"21","author":"Alomari","year":"2013","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.ctrv.2023.102619_b0495","doi-asserted-by":"crossref","unstructured":"Ibrahim F, Al Sabbagh A, Amer A, Soliman DS, Al Sabah H. Composite chronic lymphocytic leukemia\/small lymphocytic lymphoma and mantle cell lymphoma; small cell variant: a real diagnostic challenge. Case presentation and review of literature. Am J Case Rep 2020;21:e921131.","DOI":"10.12659\/AJCR.921131"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0500","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.humpath.2012.04.022","article-title":"Composite mantle cell lymphoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a clinicopathologic and molecular study","volume":"44","author":"Hoeller","year":"2013","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0505","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood.2020009288","article-title":"Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node","volume":"137","author":"Mass","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0510","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cyto.b.21512","article-title":"Composite mantle cell lymphoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"94","author":"Sun","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0515","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ajh.10459","article-title":"Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL)","volume":"75","author":"Sokol","year":"2004","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b0520","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.leu.2402553","article-title":"Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a frequent association?","volume":"16","author":"Gin\u00e9","year":"2002","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102619_b0525","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1080\/10428194.2020.1797007","article-title":"Concurrent chronic lymphocytic leukemia\/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features","volume":"61","author":"Obiorah","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2023.102619_b0530","article-title":"Synchronous or metachronous hairy cell leukemia and chronic lymphocytic leukemia: a case series and literature review","volume":"6","author":"Verma","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102619_b0535","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00267","article-title":"A Rare case of composite dural extranodal marginal zone lymphoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"9","author":"Bustoros","year":"2018","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0540","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jdv.12454","article-title":"Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature","volume":"29","author":"Ingen-Housz-Oro","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0545","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/cup.13956","article-title":"Primary cutaneous lymphomas in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a series of 12 cases","volume":"48","author":"Liu","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0550","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/DAD.0b013e318299ac17","article-title":"Leukemia cutis coexisting with dermatofibroma as the initial presentation of B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"36","author":"Maughan","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0555","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2133.2000.03679.x","article-title":"Mycosis fungoides and chronic lymphocytic leukaemia\u2013composite T-cell and B-cell lymphomas presenting in the skin","volume":"143","author":"Hull","year":"2000","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0560","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjh.18352","article-title":"Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome","volume":"198","author":"Favini","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0565","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0002-9440(10)64256-3","article-title":"Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome)","volume":"161","author":"Be\u00e0","year":"2002","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0570","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.932","article-title":"Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas","volume":"28","author":"Scandurra","year":"2010","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0575","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"De Paoli","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"10.1016\/j.ctrv.2023.102619_b0580","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102619_b0585","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","article-title":"Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"1","author":"Miller","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0590","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0595","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0600","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0605","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2023.102619_b0610","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.ctrv.2023.102619_b0615","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0620","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0625","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102619_b0630","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016272","article-title":"Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo","author":"Martines","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0635","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0640","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/2643-3230.BCD-22-0082","article-title":"In vivo modeling of CLL transformation to Richter syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities","volume":"4","author":"Ten Hacken","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0645","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34642-6","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Bros\u00e9us","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0650","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0655","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102619_b0660","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235816","article-title":"Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment","volume":"13","author":"Marvyin","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0665","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pathol.2021.04.008","article-title":"Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax","volume":"54","author":"G\u00e1ng\u00f3","year":"2022","journal-title":"Pathology"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102619_b0670","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1128\/MCB.25.14.6225-6234.2005","article-title":"Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis","volume":"25","author":"Li","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037699","article-title":"Mitochondrial structure, function and dynamics are temporally controlled by c-Myc","volume":"7","author":"Graves","year":"2012","journal-title":"PLoS One"},{"issue":"7657","key":"10.1016\/j.ctrv.2023.102619_b0680","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature22353","article-title":"The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3\u03b2 inhibition","volume":"546","author":"Varano","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0685","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/1878-0261.13115","article-title":"Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma","volume":"16","author":"Donati","year":"2022","journal-title":"Mol Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102619_b0690","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.ctrv.2023.102619_b0695","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0700","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0705","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/ijc.26322","article-title":"Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis","volume":"130","author":"Rossi","year":"2012","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0710","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value >10 represents a novel valid marker for discerning Richter's syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b0715","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3324\/haematol.2018.207068","article-title":"Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0720","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0725","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s11864-022-00973-1","article-title":"Novel approaches for the treatment of patients with Richter's syndrome","volume":"23","author":"Iannello","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0730","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0735","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0740","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.22121","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0745","first-page":"785","article-title":"Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group","volume":"34","author":"Tadmor","year":"2014","journal-title":"Anticancer Res"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102619_b0750","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194644","article-title":"Richter syndrome: from molecular pathogenesis to druggable targets","volume":"14","author":"Mouhssine","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102619_b0755","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.829983","article-title":"Biology and treatment of richter transformation","volume":"12","author":"Condoluci","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102619_b0760","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ccr3.269","article-title":"Ibrutinib and rituximab induced rapid response in refractory Richter syndrome","volume":"3","author":"Lamar","year":"2015","journal-title":"Clin Case Rep"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102619_b0765","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0770","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5717-y","volume":"19","author":"Appleby","year":"2019","journal-title":"BMC Cancer"},{"issue":"10277","key":"10.1016\/j.ctrv.2023.102619_b0775","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102619_b0780","article-title":"BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome","author":"Visentin","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102619_b0785","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2147\/OTT.S187459","article-title":"Rapid and complete response to idelalisib in a case of Richter syndrome","volume":"12","author":"Bagacean","year":"2019","journal-title":"Oncol Targets Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102619_b0790","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","article-title":"Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort","volume":"100","author":"Bouclet","year":"2021","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0795","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102619_b0800","doi-asserted-by":"crossref","unstructured":"Jain N, Ferrajoli A, Thompson P, et al. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. Blood 2021;138:1550.","DOI":"10.1182\/blood-2021-154279"},{"key":"10.1016\/j.ctrv.2023.102619_b0805","doi-asserted-by":"crossref","unstructured":"Crombie J, Tyekucheva S, Wang Z, et al. Updated results from a phase I\/II study of duvelisib and venetoclax in patients with relapsed or refractory CLL\/SLL or Richter\u2019s syndrome. Blood 2020;136.","DOI":"10.1182\/blood-2020-138811"},{"issue":"24","key":"10.1016\/j.ctrv.2023.102619_b0810","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0815","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0820","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102619_b0825","doi-asserted-by":"crossref","unstructured":"Jain N, Ferrajoli A, Basu S, et al. A phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation. Blood 2018;132(Suppl. 1):296.","DOI":"10.1182\/blood-2018-99-120355"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b0830","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0835","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102619_b0840","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102619_b0845","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102619_b0850","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2020003726","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation","volume":"5","author":"Lahoud","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0855","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3324\/haematol.2021.279033","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0860","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hemonc.2020.05.002","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: a systematic review and meta-analysis","volume":"14","author":"Aulakh","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"26","key":"10.1016\/j.ctrv.2023.102619_b0865","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0870","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.ctrv.2023.102619_b0875","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ctrv.2023.102619_b0880","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated With CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102619_b0885","doi-asserted-by":"crossref","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 2020;135(19):1650\u201360.","DOI":"10.1182\/blood.2019002936"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2023.102619_b0890","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and efficacy of CD19-CAR T cells in Richter's Transformation after targeted therapy for chronic lymphocytic leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102619_b0895","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.828471","article-title":"Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter's transformation","volume":"12","author":"Ortiz-Maldonado","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102619_b0900","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","article-title":"A phase two study of high dose blinatumomab in Richter's syndrome","volume":"36","author":"Thompson","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2023.102619_b0905","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1182\/blood-2021-147467","article-title":"Blinatumomab for patients with Richter's syndrome: a multicenter phase 2 trial from the Filo Group","volume":"138","author":"Guieze","year":"2021","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102619_b0910","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0915","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102619_b0920","doi-asserted-by":"crossref","unstructured":"Kater AP, Ye JC, Sandoval-Sus J, Bellido M, Christensen JH, Mato AT e al. Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1). Blood 2022;140(Suppl. 1):850\u20131.","DOI":"10.1182\/blood-2022-158298"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0925","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-065X.2010.00934.x","article-title":"Role of PI3K in the generation and survival of B cells","volume":"237","author":"Werner","year":"2010","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b0930","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2023.102619_b0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102619_b0940","article-title":"Phase I study of first-in-class oral triplet therapy DTRM-555 in relapsed\/refractory lymphoma patients through fixed-dose combination and synthetic lethality","volume":"132","author":"Huntington","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b0945","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/10428194.2018.1562180","article-title":"Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study","volume":"60","author":"Awan","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2023.102619_b0950","article-title":"Characterization of LP-118, a novel small molecule inhibitor of Bcl-2 and Bcl-Xl in chronic lymphocytic leukemia resistant to venetoclax","volume":"1 38: 1","author":"Ravikrishnan","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ctrv.2023.102619_b0955","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2023.102619_b0960","doi-asserted-by":"crossref","unstructured":"Wang M, Barrientos J, Furman R, et al. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid 2021;1(1).","DOI":"10.1056\/EVIDoa2100001"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2023.102619_b0970","doi-asserted-by":"crossref","unstructured":"Sharp A, Williams A, Blagden S, et al. A first\u2010in\u2010human phase 1 trial of Nx\u20101607, a first\u2010in\u2010class oral CBL\u2010B inhibitor, inpatients with advanced solid tumor malignancies. J Clin Oncol 40(16_suppl):TPS2691.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2691"},{"issue":"21","key":"10.1016\/j.ctrv.2023.102619_b0975","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102619_b0980","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102619_b0985","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102619_b0990","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102619_b0995","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b1000","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102619_b1005","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102619_b1010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2023.102619_b1015","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102619_b1020","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"10232","key":"10.1016\/j.ctrv.2023.102619_b1025","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102619_b1030","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102619_b1035","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102619_b1040","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102619_b1045","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2017-05-786988","article-title":"A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib","volume":"130","author":"Winter","year":"2017","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:31:16Z","timestamp":1759656676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":209,"alternative-id":["S0305737223001123"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102619","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102619"}}